<DOC>
	<DOCNO>NCT02544152</DOCNO>
	<brief_summary>A study efficacy safety Lubiprostone subject diagnose IBS-M/IBS-U .</brief_summary>
	<brief_title>Evaluation Efficacy Safety Lubiprostone Adults With Mixed Unsubtyped Irritable Bowel Syndrome</brief_title>
	<detailed_description>To assess efficacy safety oral lubiprostone , compare match placebo , administer orally ( 8 mcg twice daily [ BID ] ) subject diagnose IBS-M/IBS-U .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Lubiprostone</mesh_term>
	<criteria>Subject meet diagnosis IBSM IBSU confirm use adapt ROME III Diagnostic Questionnaire Adult Functional GI Disorders . Subject Screening diary entry must show average bad abdominal pain past 24 hour score least 4 11point scale . Subject must stable dose selective serotonin reuptake inhibitor ( SSRIs ) , serotoninspecific reuptake inhibitor ( SNRIs ) , monoamine oxidase inhibitor ( MAO ) inhibitor take antidepressant . Subject current diagnosis IBS diarrhea ( IBSD ) IBS constipation ( IBSC ) , accord Rome III Criteria . Any gastrointestinal ( GI ) condition , IBSrelated , affect GI motility defecation . Medical/surgical condition might interfere absorption , distribution , metabolism , excretion study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>